Since it was established in 2017, Cellino Biotech has offered an intriguing approach to stem cell therapy manufacturing, combining biology, laser physics, gene editing tools and machine learning.
In April of last year, the Cambridge, Massachusetts, startup attracted $16 million in financing. Now, nine months later, it has a major player into its corner.
Bayer said Tuesday that its investment arm, Leaps by Bayer, is leading an $80 million series A financing round for the company founded by three young Harvard graduates.
